Full-Time

Field Reimbursement Manager

Updated on 7/11/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$145.5k - $196.8k/yr

+ Discretionary Annual Bonus + Sales-based Incentive Plan + Stock-based Long-term Incentives

Miami, FL, USA

Hybrid

Three days on-site per week for patient access; 60-80% travel.

Category
Business & Strategy (1)

People at Amgen

People at Amgen who can refer or advise you

Requirements
  • Doctorate degree
  • Master’s degree and 3 years of customer service and/or leadership experience
  • Bachelor’s degree and 5 years of customer service and/or leadership experience
  • Associate’s degree and 10 years of customer service and/or leadership experience
  • High school diploma / GED and 12 years of customer service and/or leadership experience
  • In addition to meeting at least one of the above requirements, you must have experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation or resources. Your managerial experience may run concurrently with the required technical experience referenced above
Responsibilities
  • Act as an extension of the HUB, providing live one-on-one coverage support
  • Offer assistance from physician order to reimbursement, supporting the entire reimbursement journey through payer prior authorization to appeals/denials requirements and forms
  • Review patient-specific information in cases where the site has specifically requested assistance resolving any issues or coverage challenges
  • Educate and update healthcare providers (HCPs) on key private and public payer coverage and changes that impact patient product access
  • Coordinate access/reimbursement issues with relevant partners, including the HUB
  • Provide information to HCPs on how the products are covered under the benefit design (Commercial, Medicare, Medicaid)
  • Serve as a payer expert for defined geography and promptly communicate payer changes to key stakeholders
  • Offer office education during the access process, including formulary coverage/utilization management criteria, insurance forms & procedures, benefits investigation, prior authorization, appeal, and/or claims resolution
  • Educate offices using approved materials
  • Review patient insurance benefit options and alternate funding/financial assistance programs
  • Collaborate with other departments to resolve reimbursement issues
Desired Qualifications
  • Bachelor's degree in business, healthcare, or a related field
  • 6 years' experience with specialty/biologic self-injectable (pharmacy benefit) or physician-administered (buy and bill/medical benefit) products
  • Bilingual proficiency in English and Spanish, with the ability to communicate effectively in both languages
  • Advanced knowledge of medical insurance terminology
  • Knowledge of Centers of Medicare & Medicaid Services (CMS) policies and processes with expertise in Medicare (Part B – for buy & bill products and Part D for Pharmacy products)
  • Ability to manage ambiguity and problem-solve
  • Ability to manage expenses within allocated budgets
  • Strong medical reimbursement experience and/or Specialty Pharmacy and Buy & Bill knowledge
  • Proven presentation and facilitation skills
  • Strong written and oral communication skills
  • Organizational skills and project management experience, including the ability to manage multiple projects
  • Strong computer literacy, including Word, Excel, and PowerPoint, and the ability to conduct web-based meetings
  • Experience in the healthcare industry, including insurance verification, claim adjudication, physician's offices or clinics, pharmacies, and/or pharmaceutical manufacturers

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

People at Amgen

People at Amgen who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs drive 70% of sales with 24% growth, offsetting patent cliff declines[1]
  • MariTide obesity candidate shows ~20% weight loss with improved dosing tolerability[1]
  • IMDYLLTRA approval as first T-cell engager for small cell lung cancer validates oncology pipeline[1]

What critics are saying

  • Tavneos withdrawal likely within 3–6 months due to FDA data manipulation, risking $500M/year revenue[1]
  • Corlanor and Sensipar Class II recalls signal manufacturing deviations, risking supply and reputation[1]
  • IRS audit dispute over 2016–2018 taxes could cost $100M+ and trigger credit rating downgrade[1]

What makes Amgen unique

  • Dual-pillar model fuses innovative biologics with a $3B biosimilars portfolio funding R&D[2]
  • Biology-first approach uses human genetics and AI to validate targets and accelerate discovery[2]
  • World-class agile biomanufacturing ensures high-quality delivery across 100 countries[2][5]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.